Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2022-09-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物第二届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board (监事会) of Hangzhou Anxu Biotechnology Co., Ltd. regarding the resolution passed in their third meeting of the second Supervisory Board. It details the approval of a proposal to use temporarily idle funds for cash management, including voting results and compliance with relevant regulations. The document is an official meeting resolution announcement rather than a financial report, audit, or management discussion. It does not contain financial statements or detailed financial data, nor is it a call transcript or shareholder voting result announcement. It is a regulatory announcement about internal governance and financial management decisions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is short (1060 characters), and it is not an announcement of a report publication but a standalone announcement of a board resolution.
2022-09-26 Chinese
安旭生物关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) for investors. It references that the company has already published its 2022 half-year report on August 30, 2022, and this meeting is to discuss and explain that report. The document does not contain actual financial data or the report itself, but rather provides logistical information about the upcoming investor call and how investors can participate and ask questions. The document length is short (1564 characters), and it serves as a notice for an event related to the interim report rather than the report itself. Therefore, it fits best into the category of Investor Presentation (IP), as it is a detailed presentation event for investors focusing on financial results and interaction, not the report or earnings release itself.
2022-09-13 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司2022年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022年半年度持续督导跟踪报告" which translates to "2022 Semi-Annual Continuous Supervision Follow-up Report". It is issued by a securities company acting as a sponsor for a listed company, detailing continuous supervision activities, risk factors, financial data for the first half of 2022, and other operational and governance information. The document contains substantive financial data for the half-year period, including revenue, net profit, cash flow, and R&D expenditures, as well as detailed narrative on business risks and core competencies. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and includes actual financial statements and analysis. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2022
2022-09-06 Chinese
安旭生物2022年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2022 Half-Year Report Summary' (半年度报告摘要) from Hangzhou Anxu Biotechnology Co., Ltd. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a half-year report summary and includes substantive financial data and analysis for the period. It is not a short announcement or a certification but a comprehensive interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
安旭生物2022年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2022 年半年度报告" which translates to "2022 Half-Year Report". It contains detailed financial data for the first half of 2022, including revenue, net profit, earnings per share, and other financial metrics. It also includes management discussion and analysis, company business overview, core technologies, R&D progress, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report publication or a certification letter. The content matches the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year with substantive financial data and analysis. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-29 Chinese
安旭生物独立董事关于第二届董事会第二次会议相关事项的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion from the independent directors regarding the company's 2022 half-year fundraising funds deposit and actual usage special report. It confirms compliance with fundraising management regulations and agrees with the board's special report on the half-year fundraising usage. The document is short (970 characters) and primarily contains an opinion on a specific report rather than the report itself. It does not contain financial statements or detailed financial data. This fits the profile of an Audit Report / Information (AR) as it relates to a special report on fundraising usage and independent directors' opinion on it, rather than a full interim report or annual report. Therefore, the classification is AR with high confidence. H1 2022
2022-08-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.